Insight in persons with schizophrenia - Effects of switching from conventional neuroleptics to atypical antipsychotics

被引:33
|
作者
Aguglia, E [1 ]
De Vanna, M [1 ]
Onor, ML [1 ]
Ferrara, D [1 ]
机构
[1] Univ Trieste, UCO Clin Psychiat, Dept Clin Morphol & Technol Sci, I-34147 Trieste, Italy
来源
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 2002年 / 26卷 / 7-8期
关键词
atypical antipsychotics; insight; schizophrenia;
D O I
10.1016/S0278-5846(02)00242-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The primary aim of our study is to evaluate the level of insight during the switch from a classical antipsychotic drug to a atypical neuroleptic. Twenty-two schizophrenic patients were admitted to the study, 9 were male and 13 were female. Standardized questionnaire were: Scale for Assessment of Negative Symptoms (SANS), Scale for Assessment of Positive Symptoms (SAPS), Brief Psychiatric Rating Scale (BPRS) and Schedule for Assessing the three components of Insight (SAI). All patients were receiving haloperidol at time of recruitment. Eight patients were switched to clozapine, 3 to risperidone and 11 to olanzapine. The global function, measured with BPRS, increased after administration of atypical antipsychotics. The positive and negative symptoms were reduced. The level of insight was increased after the administration of the atypical antipsychotics. The cognitive effect of the atypical antipsychotics changed the level of insight and augmented the compliance. (C) 2002 Published by Elsevier Science Inc.
引用
收藏
页码:1229 / 1233
页数:5
相关论文
共 50 条
  • [41] ''Awakening'' from schizophrenia: Intramolecular polypharmacy and the atypical antipsychotics
    Stahl, SM
    JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (09) : 381 - 382
  • [42] Treatment-induced changes in factor structure of schizophrenia after switching from typical to atypical antipsychotics
    Lecyk, A
    Loza, B
    Mazurek, I
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S347 - S347
  • [43] Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia
    Bartzokis, George
    Lu, Po H.
    Nuechterlein, Keith H.
    Gitlin, Michael
    Doi, Clarissa
    Edwards, Nancy
    Lieu, Christopher
    Altshuler, Lori L.
    Mintz, Jim
    SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) : 13 - 22
  • [44] Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders
    Glick, ID
    Berg, PH
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (02) : 65 - 68
  • [45] Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics
    Scheller-Gilkey, G
    Woolwine, BJ
    Cooper, I
    Gay, O
    Moynes, KA
    Miller, AH
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2003, 29 (03): : 553 - 566
  • [46] Conversion from conventional to atypical neuroleptics - recommendations for inpatient and outpatient treatment
    Lambert, M
    Moritz, S
    Haasen, C
    Naber, D
    NERVENARZT, 2000, 71 (11): : 859 - +
  • [47] Improvement of obsessive-compulsive symptoms in schizophrenia patients after switching from typical or atypical antipsychotics to amisulpride
    Sirota, P.
    Hadi, E.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [48] EXTRAPOLATION OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA FROM ADULTS TO ADOLESCENTS
    Kalaria, Shamir
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2022, 61 (10): : S294 - S294
  • [49] From receptor to outcome: the impact of atypical antipsychotics in schizophrenia - Introduction
    Burns, T
    EUROPEAN PSYCHIATRY, 1998, 13 : 3S - 4S
  • [50] Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics
    Maes, M
    Chiavetto, LB
    Bignotti, S
    Tura, GJB
    Pioli, R
    Boin, F
    Kenis, G
    Bosmans, E
    de Jongh, R
    Lin, AH
    Racagni, G
    Altamura, CA
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2000, 10 (02) : 119 - 124